Highlight Therapeutics

Highlight Therapeutics trials second-line melanoma combo after immunotherapy fails
Pharmaforum
Wed, 09/2/20 - 10:49 am
Highlight Therapeutics
melanoma
BO-112
Keytruda
Merck